Citations (113)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (29)
Christopher B Cooper, Worawan Sirichana, Michael T Arnold, Eric V Neufeld, Michael Taylor, Xiaoyan Wang & Brett A Dolezal. (2020) Remote Patient Monitoring for the Detection of COPD Exacerbations. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 2005-2013.
Read now
Read now
Jose Luis Lopez-Campos & Stefano Centanni. (2018) Current Approaches for Phenotyping as a Target for Precision Medicine in COPD Management. COPD: Journal of Chronic Obstructive Pulmonary Disease 15:2, pages 108-117.
Read now
Read now
Martine Hoogendoorn, Talitha L Feenstra, Melinde Boland, Andrew H Briggs, Sixten Borg, Sven-Arne Jansson, Nancy A Risebrough, Julia F Slejko & Maureen PMH Rutten-van Mölken. (2017) Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 3183-3194.
Read now
Read now
DP Tashkin. (2015) The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Safety 14:11, pages 1759-1772.
Read now
Read now
Thomas R. Einarson, Basil G. Bereza, T. Anders Nielsen & Michiel E. H. Hemels. (2015) Utilities for asthma and COPD according to category of severity: a comprehensive literature review. Journal of Medical Economics 18:7, pages 550-563.
Read now
Read now
Joohae Kim, Ho Il Yoon, Yeon-Mok Oh, Seong Yong Lim, Ji-Hyun Lee, Tae-Hyung Kim, Sang Yeub Lee, Jin Hwa Lee, Sang-Do Lee & Chang-Hoon Lee. (2015) Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 1819-1827.
Read now
Read now
D van Ranst, WA Stoop, JW Meijer, HJ Otten & IG van de Port. (2014) Reduction of exacerbation frequency in patients with COPD after participation in a comprehensive pulmonary rehabilitation program. International Journal of Chronic Obstructive Pulmonary Disease 9, pages 1059-1067.
Read now
Read now
David MG Halpin, Marc Decramer, Bartolome Celli, Steven Kesten, Dacheng Liu & Donald P Tashkin. (2012) Exacerbation frequency and course of COPD. International Journal of Chronic Obstructive Pulmonary Disease 7, pages 653-661.
Read now
Read now
Lucas MA Goossens, Christine L Baker, Brigitta U Monz, Kelly H Zou & Maureen PMH Rutten-van Mölken. (2011) Adjusting for COPD severity in database research: developing and validating an algorithm. International Journal of Chronic Obstructive Pulmonary Disease 6, pages 669-678.
Read now
Read now
Donald P Tashkin. (2010) Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT® trial. Expert Review of Respiratory Medicine 4:3, pages 279-289.
Read now
Read now
Kenneth R. Chapman, Robert A. Stockley, Mahlon M. Wilkes & Roberta J. Navickis. (2010) Letter to the Editor Response. COPD: Journal of Chronic Obstructive Pulmonary Disease 7:3, pages 235-236.
Read now
Read now
Dong-Churl Suh, Helen Lau, Hyen-Oh La, In-sun Choi & Gregory P. Geba. (2010) Association between incidence of acute exacerbation and medication therapy in patients with COPD. Current Medical Research and Opinion 26:2, pages 297-306.
Read now
Read now
Terence AR Seemungal, John R Hurst & Jadwiga A Wedzicha. (2009) Exacerbation rate, health status and mortality in COPD – a review of potential interventions. International Journal of Chronic Obstructive Pulmonary Disease 4, pages 203-223.
Read now
Read now
Kai-Michael Beeh, Bettina Hederer, Thomas Glaab, Achim Müller, Maureen Rutten-van Moelken, Steven Kesten & Claus Vogelmeier. (2009) Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. International Journal of Chronic Obstructive Pulmonary Disease 4, pages 119-125.
Read now
Read now
Marc Miravitlles & Antonio Anzueto. (2009) Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT® studies. International Journal of Chronic Obstructive Pulmonary Disease 4, pages 185-201.
Read now
Read now
Kenneth R. Chapman, Robert A. Stockley, Clara Dawkins, Mahlon M. Wilkes & Roberta J. Navickis. (2009) Augmentation Therapy for α1 Antitrypsin Deficiency: A Meta-Analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease 6:3, pages 177-184.
Read now
Read now
Alex Chee & Don D Sin. (2008) Treatment of mild chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 3:4, pages 563-573.
Read now
Read now
A-B Tonnel, T Perez, J-M Grosbois, C Verkindre, M-L Bravo & M Brun. (2008) Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. International Journal of Chronic Obstructive Pulmonary Disease 3:2, pages 301-310.
Read now
Read now
M. Johnson, A. G. N. Agusti & N. C. Barnes. (2008) Reflections on TORCH: Potential Mechanisms for the Survival Benefit of Salmeterol/Fluticasone Propionate in COPD Patients. COPD: Journal of Chronic Obstructive Pulmonary Disease 5:6, pages 369-375.
Read now
Read now
Dennis E. Doherty. (2008) A Review of the Role of FEV1 in the COPD Paradigm. COPD: Journal of Chronic Obstructive Pulmonary Disease 5:5, pages 310-318.
Read now
Read now
Marc Decramer, Stephen Rennard, Thierry Troosters, Douglas W. Mapel, Nicholas Giardino, David Mannino, Emiel Wouters, Sanjay Sethi & Christopher B. Cooper. (2008) COPD as a Lung Disease with Systemic Consequences – Clinical Impact, Mechanisms, and Potential for Early Intervention. COPD: Journal of Chronic Obstructive Pulmonary Disease 5:4, pages 235-256.
Read now
Read now
Andrea S. Gershon, Li Wang, Teresa To, Jin Luo & Ross E.G. Upshur. (2008) Survival with Tiotropium Compared to Long-Acting Beta-2-Agonists in Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease 5:4, pages 229-234.
Read now
Read now
David Halpin. (2008) Mortality in COPD: Inevitable or Preventable? Insights from the Cardiovascular Arena. COPD: Journal of Chronic Obstructive Pulmonary Disease 5:3, pages 187-200.
Read now
Read now
Richard Russell & Dave Singh. (2007) Which bronchodilator in COPD?. International Journal of Chronic Obstructive Pulmonary Disease 2:2, pages 93-94.
Read now
Read now
Terence Seemungal, Robert Stockley, Peter Calverley, Gerry Hagan & Jadwiga A. Wedzicha. (2007) Investigating New Standards for Prophylaxis in Reduction of Exacerbations—The INSPIRE Study Methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease 4:3, pages 177-183.
Read now
Read now
David Price. (2006) The effect of tiotropium bromide on health-related quality of life in chronic obstructive pulmonary disease. Expert Review of Pharmacoeconomics & Outcomes Research 6:4, pages 391-405.
Read now
Read now
David M Mannino & Victor A Kiri. (2006) Changing the burden of COPD mortality. International Journal of Chronic Obstructive Pulmonary Disease 1:3, pages 219-233.
Read now
Read now
Thomas Glaab, Norbert Banik, Olivier T. Rutschmann & Marion Wencker. (2006) National Survey of Guideline-Compliant COPD Management Among Pneumologists and Primary Care Physicians. COPD: Journal of Chronic Obstructive Pulmonary Disease 3:3, pages 141-148.
Read now
Read now
James F. Donohue. (2005) Minimal Clinically Important Differences in COPD Lung Function. COPD: Journal of Chronic Obstructive Pulmonary Disease 2:1, pages 111-124.
Read now
Read now
Articles from other publishers (84)
Mykola M. Ostrovskyy, Mariana O. Kulynych-Miskiv, Khrystyna I. Volnytska, Lilia Dm. Todoriko, Kseniia M. Ostrovska, Oleksandr I. Varunkiv & Iryna O. Savelikhina. (2022) NEW POSSIBILITIES FOR MODIFYING THE COURSE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: THE EFFECT OF TIOTROPIUM BROMIDE ON CERTAIN PATHOGENETIC LINKS OF NEOCOLLAGENOGENESIS AND LOCAL IMMUNE DEFENCE OF THE BRONCHIAL TREE. Wiadomości Lekarskie 75:2, pages 473-477.
Crossref
Crossref
Suyun Yu, Caili Zhang, Zhijun Yan, Qingqing Fang & Xiwen Gao. (2021) Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease. Computational and Mathematical Methods in Medicine 2021, pages 1-6.
Crossref
Crossref
Heshen Tian, Yumin Zhou, Longhui Tang, Fan Wu, Zhishan Deng, Bijia Lin, Peiyu Huang, Shaodan Wei, Dongxing Zhao, Jingping Zheng, Nanshan Zhong & Pixin Ran. (2020) High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I–II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China. Trials 21:1.
Crossref
Crossref
Klaus F. Rabe, David M. G. Halpin, MeiLan K. Han, Marc Miravitlles, Dave Singh, Lars Grönke, Florian Voß & Fernando J. Martinez. (2020) Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. Respiratory Research 21:1.
Crossref
Crossref
LianHong Wang, KaiLi Wu, XiDong Chen & Qilan Liu. (2019) The Effects of Tai Chi on Lung Function, Exercise Capacity and Health Related Quality of Life for Patients With Chronic Obstructive Pulmonary Disease: A Pilot Study. Heart, Lung and Circulation 28:8, pages 1206-1212.
Crossref
Crossref
Jenny V. Suneby Jagers, Michael Ji, Bruce Rothwell & Paul A. Easton. (2019) Aminophylline increases parasternal muscle action in awake canines. Pulmonary Pharmacology & Therapeutics 56, pages 1-7.
Crossref
Crossref
Donald P. Tashkin, Marc Miravitlles, Bartolomé R. Celli, Norbert Metzdorf, Achim Mueller, David M. G. Halpin & Antonio Anzueto. (2018) Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial. Respiratory Research 19:1.
Crossref
Crossref
Jose Luis Lopez-Campos, Laura Carrasco Hernández, Xavier Muñoz, Víctor Bustamante & Esther Barreiro. (2018) Current controversies in the stepping up and stepping down of inhaled therapies for COPD at the patient level. Respirology 23:9, pages 818-827.
Crossref
Crossref
Margarita Capel, María Mareque, Carlos José Álvarez, Leandro Lindner & Itziar Oyagüez. (2018) Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment. Clinical Drug Investigation 38:7, pages 611-620.
Crossref
Crossref
Wouter Poortinga, Sarah E Rodgers, Ronan A Lyons, Pippa Anderson, Chris Tweed, Charlotte Grey, Shiyu Jiang, Rhodri Johnson, Alan Watkins & Thomas G Winfield. (2018) The health impacts of energy performance investments in low-income areas: a mixed-methods approach. Public Health Research 6:5, pages 1-182.
Crossref
Crossref
Donald P Tashkin, Ning Li, Eric C Kleerup, David Halpin, Bartolome Celli, Marc Decramer & Robert Elashoff. (2014) Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD. Respiratory Research 15:1.
Crossref
Crossref
Lei Wu, Anthony Lin Zhang, Yuan Ming Di, Johannah Linda Shergis, Yuanbin Chen, Xinfeng Guo, Zehuai Wen, Francis Thien, Christopher Worsnop, Lin Lin & Charlie Changli Xue. (2014) Panax ginseng therapy for chronic obstructive pulmonary disease: a clinical trial protocol and pilot study. Chinese Medicine 9:1.
Crossref
Crossref
Lucas M A Goossens, Inge Leimer, Norbert Metzdorf, Karin Becker & Maureen P M H Rutten-van Mölken. (2014) Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulmonary Medicine 14:1.
Crossref
Crossref
Charlotta Karner, Jimmy Chong & Phillippa Poole. (2014) Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2016:11.
Crossref
Crossref
Kayleigh M Kew, Sofia Dias & Christopher J Cates. (2014) Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Vito Brusasco & Fernando Martinez. 2011. Comprehensive Physiology. Comprehensive Physiology
1
31
.
Takanori Ayabe, Masaki Tomita, Eiichi Chosa, Katsuya Kawagoe & Kunihide Nakamura. (2014) Effect of Inhaled Tiotropium as the Perioperative Management of Patients Undergoing Pulmonary Resection for Primary Lung Cancer. Journal of Cancer Therapy 05:09, pages 845-859.
Crossref
Crossref
Pierre-R?gis Burgel, Jean-Louis Paillasseur, Daniel Dusser, Nicolas Roche, Dacheng Liu, Yufeng Liu, Armin Furtwaengler, Norbert Metzdorf & Marc Decramer. (2014) Tiotropium might improve survival in subjects with COPD at high risk of mortality. Respiratory Research 15:1, pages 64.
Crossref
Crossref
W. Janssens, Y. Liu, D. Liu, S. Kesten, D.P. Tashkin, B.R. Celli & M. Decramer. (2013) Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT®). Respiratory Medicine 107:9, pages 1409-1416.
Crossref
Crossref
Roozbeh Sharif, Christel R. Cuevas, Yue Wang, Mohit Arora & Gulshan Sharma. (2013) Guideline adherence in management of stable chronic obstructive pulmonary disease. Respiratory Medicine 107:7, pages 1046-1052.
Crossref
Crossref
Loes E.M. Kistemaker, Tjitske A. Oenema, Herman Meurs & Reinoud Gosens. (2012) Regulation of airway inflammation and remodeling by muscarinic receptors: Perspectives on anticholinergic therapy in asthma and COPD. Life Sciences 91:21-22, pages 1126-1133.
Crossref
Crossref
Heather Parsons, Rachel Damico & Venkataramana Sidhaye. 2012. Pulmonary Nanomedicine. Pulmonary Nanomedicine
235
257
.
Charlotta Karner, Jimmy Chong & Phillippa Poole. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Lorcan P. McGarvey, Sheldon Magder, Deborah Burkhart, Steven Kesten, Dacheng Liu, Raymond C. Manuel & Denis E. Niewoehner. (2012) Cause-specific mortality adjudication in the UPLIFT? COPD trial: Findings and recommendations. Respiratory Medicine 106:4, pages 515-521.
Crossref
Crossref
Bartolome R Celli, Marc Decramer, Theodore Lystig, Steven Kesten & Donald P Tashkin. (2012) Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respiratory Research 13:1, pages 66.
Crossref
Crossref
Nicola A Hanania, Amir Sharafkhaneh, Bartolome Celli, Marc Decramer, Ted Lystig, Steven Kesten & Donald Tashkin. (2011) Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research 12:1.
Crossref
Crossref
Steven Kesten, Bartolome Celli, Marc Decramer, Dacheng Liu & Donald Tashkin. (2011) Adverse health consequences in COPD patients with rapid decline in FEV1 - evidence from the UPLIFT trial. Respiratory Research 12:1.
Crossref
Crossref
Marc Decramer, Geert Molenberghs, Dacheng Liu, Bartolome Celli, Steven Kesten, Theodore Lystig & Donald P. Tashkin. (2011) Premature discontinuation during the UPLIFT study. Respiratory Medicine 105:10, pages 1523-1530.
Crossref
Crossref
David M. G. Halpin, Marc Decramer, Bartolome Celli, Steven Kesten, Inge Leimer & Donald P. Tashkin. (2011) Risk of Nonlower Respiratory Serious Adverse Events Following COPD Exacerbations in the 4-year UPLIFT? Trial. Lung 189:4, pages 261-268.
Crossref
Crossref
YOSHINOSUKE FUKUCHI, LENORA FERNANDEZ, HAN-PIN KUO, AZIAH MAHAYIDDIN, BARTOLOME CELLI, MARC DECRAMER, STEVEN KESTEN, DACHENG LIU & DONALD TASHKIN. (2011) Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology 16:5, pages 825-835.
Crossref
Crossref
Bartolome R. Celli. 2011. COPD. COPD
81
98
.
Donald Tashkin, Bartolome Celli, Steven Kesten, Ted Lystig & Marc Decramer. (2010) Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFT? trial. Respiratory Medicine 104:10, pages 1495-1504.
Crossref
Crossref
Mark T Dransfield, William Bailey, Glenn Crater, Amanda Emmett, Dianne M O'Dell & Barbara Yawn. (2010) Disease severity and symptoms among patients receiving monotherapy for COPD. Primary Care Respiratory Journal 20:1, pages 46-53.
Crossref
Crossref
Nicola A. Hanania, David M. Mannino, Barbara P. Yawn, Douglas W. Mapel, Fernando J. Martinez, James F. Donohue, Mark Kosinski, Regina Rendas-Baum, Matthew Mintz, Steven Samuels, Priti Jhingran & Anand A. Dalal. (2010) Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). Respiratory Medicine 104:8, pages 1160-1170.
Crossref
Crossref
E.D. Bateman, S. Rennard, P.J. Barnes, P.V. Dicpinigaitis, R. Gosens, N.J. Gross, J.A. Nadel, M. Pfeifer, K. Racké, K.F. Rabe, B.K. Rubin, T. Welte & I. Wessler. (2009) Alternative mechanisms for tiotropium. Pulmonary Pharmacology & Therapeutics 22:6, pages 533-542.
Crossref
Crossref
Bartolome Celli, Marc Decramer, Steven Kesten, Dacheng Liu, Sunil Mehra & Donald P. Tashkin. (2009) Mortality in the 4-Year Trial of Tiotropium (UPLIFT) in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine 180:10, pages 948-955.
Crossref
Crossref
Marc Decramer, Bartolome Celli, Steven Kesten, Theodore Lystig, Sunil Mehra & Donald P Tashkin. (2009) Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. The Lancet 374:9696, pages 1171-1178.
Crossref
Crossref
С.И. ОвчаренкоВ.А. Капустина. (2009) Хроническая обструктивная болезнь легких: особенности
у женщин. PULMONOLOGIYA:2, pages 102-112.
Crossref
Crossref
Gaetano Caramori, Ian M. Adcock & Alberto Papi. (2009) Clinical Definition of COPD Exacerbations and Classification of Their Severity. Southern Medical Journal 102:3, pages 277-282.
Crossref
Crossref
A. Gillissen. (2009) Tiotropium in der Langzeittherapie bei COPDTiotropium in long-term treatment of COPD. Der Pneumologe 6:2, pages 111-112.
Crossref
Crossref
. (2009) Tiotropium in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine 360:2, pages 185-187.
Crossref
Crossref
Didier Saey, Nad?ge Gosselin, Marc Decramer & Thierry Troosters. 2009. Kin?sith?rapie respiratoire. Kin?sith?rapie respiratoire
159
171
.
Stephen I. Rennard. 2009. Asthma and COPD. Asthma and COPD
823
836
.
Trevor T. Hansel, Andrew J. Tan, Peter J. Barnes & Onn Min Kon. 2009. Asthma and COPD. Asthma and COPD
615
626
.
Fabrizio Luppi, Bianca Beghè, Lorenzo Corbetta & Leonardo M. Fabbri. 2009. Asthma and COPD. Asthma and COPD
523
541
.
I. E. Stepanyan. (2008) Effect of long-term treatment with tiotropium bromide on lung function in patients with chronic obstructive pulmonary disease (the UPLIFT trial). PULMONOLOGIYA:6, pages 90-94.
Crossref
Crossref
Andrea M Chen, Suzanne G Bollmeier & Patrick M Finnegan. (2008) Long-Acting Bronchodilator Therapy for the Treatment of Chronic Obstructive Pulmonary Disease. Annals of Pharmacotherapy 42:12, pages 1832-1842.
Crossref
Crossref
Jan B. Oostenbrink, Maiwenn J. Al, Mark Oppe & Maureen P.M.H. Rutten-van M?lken. (2008) Expected Value of Perfect Information: An Empirical Example of Reducing Decision Uncertainty by Conducting Additional Research. Value in Health 11:7, pages 1070-1080.
Crossref
Crossref
M. Decramer. (2008) Éclairage apporté par les essais cliniques avec le tiotropium. Revue des Maladies Respiratoires 25:10, pages 21-24.
Crossref
Crossref
Nicholas J. Gross. (2008) Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation. Mayo Clinic Proceedings 83:11, pages 1241-1250.
Crossref
Crossref
Donald P. Tashkin, Bartolome Celli, Stephen Senn, Deborah Burkhart, Steven Kesten, Shailendra Menjoge & Marc Decramer. (2008) A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine 359:15, pages 1543-1554.
Crossref
Crossref
N. Roche. (2008) Histoire naturelle de la BPCO?: des grandes ?tudes ? la pratique. Revue des Maladies Respiratoires 25:8, pages 16-19.
Crossref
Crossref
Todd A. LeeA. Simon PickardDavid H. AuBrian BartleKevin B. Weiss. (2008) Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary Disease. Annals of Internal Medicine 149:6, pages 380.
Crossref
Crossref
Stephen I. Rennard & Jørgen Vestbo. (2008) The Many “Small COPDs”. Chest 134:3, pages 623-627.
Crossref
Crossref
Patricia Macedo & Omar S. Usmani. (2008) Inhaled Drug Therapy in Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine 15:5, pages 239-247.
Crossref
Crossref
Bartolomé R. Celli, Nicola E. Thomas, Julie A. Anderson, Gary T. Ferguson, Christine R. Jenkins, Paul W. Jones, Jørgen Vestbo, Katharine Knobil, Julie C. Yates & Peter M. A. Calverley. (2008) Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine 178:4, pages 332-338.
Crossref
Crossref
Christopher B. Cooper & Mark Dransfield. (2008) Primary Care of the Patient with Chronic Obstructive Pulmonary Disease?Part 4: Understanding the Clinical Manifestations of a Progressive Disease. The American Journal of Medicine 121:7, pages S33-S45.
Crossref
Crossref
Nicholas Gross & David Levin. (2008) Primary Care of the Patient with Chronic Obstructive Pulmonary Disease?Part 2: Pharmacologic Treatment Across All Stages of Disease. The American Journal of Medicine 121:7, pages S13-S24.
Crossref
Crossref
Bartolome R. Celli. (2008) Update on the Management of COPD. Chest 133:6, pages 1451-1462.
Crossref
Crossref
Bartolome R. Celli, Claudia G. Cote, Suzanne C. Lareau & Paula M. Meek. (2008) Predictors of Survival in COPD: More than Just the FEV1. Respiratory Medicine 102, pages S27-S35.
Crossref
Crossref
J. Moita, C. Bárbara, J. Cardoso, R. Costa, M. Sousa, J. Ruiz & M.L. Santos. (2008) Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulmonary Pharmacology & Therapeutics 21:1, pages 146-151.
Crossref
Crossref
Juan Jos? Soler Catalu?a & Miguel ?ngel Mart?nez Garc?a. (2007) Factores pron?sticos en la EPOC. Archivos de Bronconeumolog?a 43:12, pages 680-691.
Crossref
Crossref
S. Nitschmann & G. Schultze-Werninghaus. (2007) Auswirkungen der COPD-Therapie auf das PatientenüberlebenImpact of COPD therapy on patient survival: the TORCH study (TOwards a Revolution in COPD Health). Der Internist 48:12, pages 1450-1452.
Crossref
Crossref
Nicola A. Hanania. (2007) Optimizing Maintenance Therapy for Chronic Obstructive Pulmonary Disease: Strategies for Improving Patient-Centered Outcomes. Clinical Therapeutics 29:10, pages 2121-2133.
Crossref
Crossref
Nicola A. Hanania & Amir Sharafkhaneh. (2007) Update on the Pharmacologic Therapy for Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine 28:3, pages 589-607.
Crossref
Crossref
Antonio Anzueto. (2007) Disease Modification in Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine 28:3, pages 609-616.
Crossref
Crossref
Peter MA Calverley & Stephen I Rennard. (2007) What have we learned from large drug treatment trials in COPD?. The Lancet 370:9589, pages 774-785.
Crossref
Crossref
Robert A. Wise & Donald P. Tashkin. (2007) Optimizing Treatment of Chronic Obstructive Pulmonary Disease: An Assessment of Current Therapies. The American Journal of Medicine 120:8, pages S4-S13.
Crossref
Crossref
C.P. van Schayck, P.J.E. Bindels, M. Decramer, P.N.R. Dekhuijzen, H.A.M. Kerstjens, J.W.M. Muris, G.M. Asijee & C. Spreeuwenberg. (2007) Making COPD a treatable disease?An integrated care perspective. Respiratory Medicine: COPD Update 3:2, pages 49-56.
Crossref
Crossref
Maureen P. M. H. Rutten-van Mölken, Jan B. Oostenbrink, Marc Miravitlles & Brigitta U. Monz. (2007) Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. The European Journal of Health Economics 8:2, pages 123-135.
Crossref
Crossref
V. A. Ignatiev, O. N. Titova, M. A. Kameneva & O. A. Sukhovskaya. (2007) Experience of long-term treatment with tiotropium bromide of patients with chronic obstructive pulmonary disease. PULMONOLOGIYA:2, pages 74-78.
Crossref
Crossref
Klaus F. Rabe. (2007) Treating COPD ? The TORCH Trial, P Values, and the Dodo. New England Journal of Medicine 356:8, pages 851-854.
Crossref
Crossref
Juan Jos? Soler Catalu?a & Miguel ?ngel Mart?nez Garc?a. (2007) Prognostic Factors in Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumolog?a ((English Edition)) 43:12, pages 680-691.
Crossref
Crossref
Didier Saey, Nad?ge Gosselin, Marc Decramer & Thierry Troosters. 2007. Kin?sith?rapie respiratoire. Kin?sith?rapie respiratoire
135
147
.
Robert A. Stockley, Stephen I. Rennard, Klaus Rabe & Bartolome CelliJoan B. Soriano. 2007. Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Disease
792
804
.
Maureen P.M.H. Rutten-van M?lken, Jan B. Oostenbrink, Donald P. Tashkin, Deborah Burkhart & Brigitta U. Monz. (2006) Does Quality of Life of COPD Patients as Measured by the Generic EuroQol Five-Dimension Questionnaire Differentiate Between COPD Severity Stages?. Chest 130:4, pages 1117-1128.
Crossref
Crossref
Donald P. Tashkin. (2006) The Role of Patient-Centered Outcomes in the Course of Chronic Obstructive Pulmonary Disease: How Long-Term Studies Contribute to Our Understanding. The American Journal of Medicine 119:10, pages 63-72.
Crossref
Crossref
Claudia G. Cote. (2006) Surrogates of Mortality in Chronic Obstructive Pulmonary Disease. The American Journal of Medicine 119:10, pages 54-62.
Crossref
Crossref
Antonio Anzueto. (2006) Clinical Course of Chronic Obstructive Pulmonary Disease: Review of Therapeutic Interventions. The American Journal of Medicine 119:10, pages 46-53.
Crossref
Crossref
Graeme P. Currie, Catherine Rossiter, Sean A. Miles, Daniel K.C. Lee & Owen J. Dempsey. (2006) Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics 19:2, pages 112-119.
Crossref
Crossref
Bartolome Celli, Roger Goldstein, Jos? Jardim & Katharine Knobil. (2005) Future perspectives in COPD. Respiratory Medicine 99, pages S41-S48.
Crossref
Crossref
R Graham Barr, Jean Bourbeau & Carlos A Camargo Jr. (2005) Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2013:1.
Crossref
Crossref
James F Donohue. (2005) Still looking for answers in COPD. The Lancet 365:9470, pages 1518-1520.
Crossref
Crossref
Tsuyoshi Ohmura & Hidekazu Nishikawa. (2005) . Folia Pharmacologica Japonica 125:5, pages 307-313.
Crossref
Crossref